Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kevin Lindell"'
Autor:
Caron Jacobson, Matthew J Frigault, Nora Horick, Areej R El-Jawahri, Kevin Lindell, Dustin J Rabideau, P Connor Johnson, Alisha Yi, Mahmoud R Gaballa, Gabriel D DePinho
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Chimeric antigen receptor (CAR) T-cell therapy recipients may receive bridging therapy while awaiting product manufacturing to control disease. Yet, data are lacking regarding the impact of bridging therapy use on clinical outcomes.Methods
Externí odkaz:
https://doaj.org/article/e2c29abb29b847ad9400146f5ffa24b3
Autor:
Marc Wehrli, Marcela V Maus, Matthew J Frigault, Mark B Leick, Nora Horick, Paul O'Donnell, Kathleen Gallagher, Yi-Bin Chen, Steven L McAfee, Areej R El-Jawahri, Zachariah DeFilipp, Thomas Spitzer, Bimal Dey, Daniella Cook, Michael Trailor, Kevin Lindell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/10c1819e606a475e82bdbd71febdb0e1
Autor:
Marc Wehrli, Kathleen Gallagher, Yi-Bin Chen, Mark B Leick, Steven L McAfee, Areej R El-Jawahri, Zachariah DeFilipp, Nora Horick, Paul O'Donnell, Thomas Spitzer, Bimal Dey, Daniella Cook, Michael Trailor, Kevin Lindell, Marcela V Maus, Matthew J Frigault
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
In addition to remarkable antitumor activity, chimeric antigen receptor (CAR) T-cell therapy is associated with acute toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Current treat
Autor:
P Connor Johnson, Caron Jacobson, Alisha Yi, Mahmoud R Gaballa, Nora Horick, Dustin J Rabideau, Kevin Lindell, Gabriel D DePinho, Areej R El-Jawahri, Matthew J Frigault
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004567
BackgroundChimeric antigen receptor (CAR) T-cell therapy recipients may receive bridging therapy while awaiting product manufacturing to control disease. Yet, data are lacking regarding the impact of bridging therapy use on clinical outcomes.MethodsW
Autor:
Hana Cho, Betsy Valles, Matthew J. Frigault, Kathleen Gallagher, Kevin Lindell, Keagan S Casey, Justin Chou, Adrian Bot, Nora Horick, Marc Wehrli, Rhine R. Shen, Simone Filosto, Jami Brown, Michael Trailor, Marcela V. Maus
Publikováno v:
Blood. 138:2814-2814
Introduction: Chimeric antigen receptor (CAR)-T cell therapy is limited in most cases to inpatient use due to risk of severe treatment-related toxicities. The two primary toxicities observed with CAR-T therapy, cytokine release syndrome (CRS) and neu
Autor:
Areej El-Jawahri, Justin T. Jordan, Kathleen Gallagher, Katelin Katsis, Yi-Bin Chen, Michael Trailor, Daniella Cook, Tracy T. Batchelor, Scott R. Plotkin, Thomas R. Spitzer, Kevin Lindell, Zachariah DeFilipp, Jorg Dietrich, Nora Horick, Steven L. McAfee, Matthew J. Frigault, Mark Roschewski, Deborah Forst, Bimalangshu R. Dey, Paul O'Donnell, Keagan S Casey, Irene Scarfò, Marcela V. Maus
Publikováno v:
Blood. 138:258-258
Background: Three CD19 directed CAR-T products have gained FDA approval for systemic large B-cell lymphoma. Due to heightened concerns of immune cell associated neurotoxicity syndrome (ICANS), patients with primary CNS lymphoma (PCNSL) were excluded
Conference
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.